新闻
CTMX
--
0.00%
--
每日生物技术脉搏:ObsEva 的外授权交易激增,EyeGate 任命新首席执行官,默克的 2 个积极催化剂,Candel Therapeutics 首次亮相
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 2天前
周一触及 52 周低点的股票
    Monday morning saw 115 companies set new 52-week lows.
Benzinga · 3天前
每日生物技术脉搏:强生、诺华报告可靠结果,Chembio 在 COVID 测试订单上飙升,Lumos 表示临床试验延迟
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:52
每日生物技术脉搏:Ardelyx 因监管挫折而下沉,AnPac 发布积极的预告,欧洲对 Myovant 点头,HCW Biologics 在华尔街首次亮相
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Benzinga · 07/20 12:19
The Daily Biotech Pulse:Moderna 加入标准普尔 500 指数,不赞成 FibroGen 的贫血药物,Corvus 搁置 COVID 研究
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
The Daily Biotech Pulse:ScPharma 的积极数据,礼来去购物,LeMaitre 预先宣布第二季度收入
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 11:48
周二触及 52 周低点的股票
    Before 10 a.m. ET on Tuesday, 48 companies set new 52-week lows.
Benzinga · 07/13 15:40
The Daily Biotech Pulse:礼来、Morphic 在 ECCO 的积极数据,Humanigen 的 COVID 治疗在英国获得加速审查,TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 11:36
The Daily Biotech Pulse:安进哮喘治疗的优先审查,Evaxion 报告阳性皮肤癌读数,Quidel 召回 Lyra COVID-19 测试
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 07/08 11:45
周三触及 52 周低点的股票
  Before 10 a.m. ET on Wednesday, 49 companies set new 52-week lows.
Benzinga · 07/07 14:01
The Daily Biotech Pulse:Opiant 数据飙升,OncoSec 因默克合作而上涨,XBiotech 特别股息
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6)
Benzinga · 07/07 11:41
内幕趋势:内幕延长了 CytomX Therapeutics 的 90 天销售趋势
MT Newswires · 06/21 16:08
简报-Cytomx Therapeutics 宣布在临床癌症研究中发布 Cx-2029 的首个人类数据
reuters.com · 06/21 12:06
CytomX Therapeutics 宣布在临床癌症研究中发布 CX-2029 的首个人类数据
CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology
Benzinga · 06/21 12:01
从周五开始的 44 个最大的推动者
Gainers
Benzinga · 06/01 09:21
周五盘中交易中的12种保健股
 
Benzinga · 05/28 16:32
华尔街中午走高,忽略通货膨胀计的上涨
MT Newswires · 05/28 13:25
巴克莱将CytomX Therapeutics从等权重降至减持,目标价从9美元下调至7美元
MT Newswires · 05/28 06:13
瑞穗证券发布对CytomX Therapeutics(CTMX)的买入评级
Mizuho Securities analyst Mara Goldstein assigned a Buy rating to CytomX Therapeutics (CTMX) yesterday and set a price target of $16.00. The company's
SmarterAnalyst · 05/07 03:05
微牛提供丰富的实时CTMX股票新闻,让你可以通过多个平台了解CTMX股票行情最新动态,这些免费的CytomX医疗新闻可以帮助你做出明智投资。
CTMX 简况
CytomX Therapeutics, Inc.是一家专注于肿瘤科的生物制药公司。该公司基于其“Probody”技术平台从事抗体疗法的开发业务。该公司利用其平台开发针对临床验证目标的免疫治疗方案并开发治疗不同癌症的疗法。“Probody”疗法包括通过标准抗体生产方法生产的三大成分(作为单一蛋白)。这三大成分包括活性癌症抗体、抗体屏蔽物以及蛋白酶易劈链接。“Probody”候选产品CX-072靶向程序性死亡因子配体1(PD-L1)。CX-072依照靶向PD-L1的单克隆抗体制造。其候选产品CX-2009靶向CD-166。该公司正在开发一种程序性细胞死亡蛋白1(PD-1)“Probody”疗法,用于封锁PD-L1或PD-1通路。该公司还开展整合素alpha3抗原“Probody”药物结合物(PDC)计划。